Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year

Long term holders of Gilead Sciences NASDAQ GILD enjoyed some market thumping gains in years past but concern over sagging hepatitis C antiviral sales caused the stock to slide about 26 5 in 2016 Despite a generally bleak year for Gilead and for biotech stocks in general